Hightide Therapeutics Inc (2511) AI Stock Analysis

• Market Cap: HK$1.38B
• Dividend Yield: N/A
• Average Volume (3M): 1.41M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.41
• Revenue Growth: N/A
• EPS Growth: 47.42%
• Country: HK
• Employees: 70
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.30
• Shares Outstanding: 571,325,700
• 10 Day Avg. Volume: 641,080
• 30 Day Avg. Volume: 1,410,076
• PEG Ratio: 17.88
• Price to Book (P/B): 1.27
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.80
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: HK$3.00 ▼(-1.64% Downside)

The score is primarily held back by weak financial performance (no revenue, ongoing cash burn, and increased debt despite improved losses). Technical indicators are mixed with neutral momentum and negative MACD, while valuation remains constrained by losses and the absence of a dividend yield.

Positive Factors

Clinical Trial Success

The success of HTD1801 in Phase III trials positions it as a potential foundational therapy, enhancing the company's product pipeline and market potential.

Governance Improvement

The establishment of a Nomination Committee aligns with best practices, potentially improving transparency, board oversight, and investor confidence.

Product Pipeline Development

HTD1801's renal benefits support the strategic focus on comprehensive treatments, enhancing the company's competitive position in metabolic disease management.

Negative Factors

Cash Burn

Persistent negative cash flow indicates reliance on external funding, increasing financial risk and potential dilution for shareholders.

No Revenue Generation

The lack of revenue generation highlights a pre-commercial profile, elevating execution and funding risks despite improved loss trajectory.

Rising Debt Levels

Increased debt levels, while manageable, add financial strain and could impact long-term stability if revenue generation does not commence.

Hightide Therapeutics Inc Business Overview & Revenue Model

Company Description

HighTide Therapeutics, Inc., an investment holding company, engages in the discovery, research and development, and commercialization of multifunctional therapies for the treatment of metabolic and digestive diseases with unmet medical needs. Its lead product candidate is HTD1801, a gut-liver anti-inflammatory metabolic modulator that targets metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus, severe hypertriglyceridemia, primary sclerosing cholangitis, and primary biliary cholangitis. The company is also developing HTD4010, a polypeptide drug for the treatment of alcoholic hepatitis; HTD1804 to treat obesity; HTD1805, a multifunctional small molecule drug for the treatment of metabolic diseases; and HTD2802 for the treatment of inflammatory bowel disease. HighTide Therapeutics, Inc. was founded in 2011 and is headquartered in Shenzhen, China.

How the Company Makes Money

Hightide Therapeutics Inc generates revenue through the development and commercialization of its proprietary drug candidates. The company earns money by advancing its product pipeline through clinical trials and securing regulatory approvals for its therapies. Revenue streams include potential partnerships and licensing agreements with other pharmaceutical companies, which can provide milestone payments and royalties. Additionally, Hightide may receive funding through collaborations with research institutions and government grants aimed at supporting innovative healthcare solutions. These partnerships and collaborations are significant contributors to the company's earnings, allowing it to fund ongoing research and development activities.

Hightide Therapeutics Inc Financial Statement Overview

Summary

Hightide Therapeutics Inc faces significant financial challenges typical for early-stage biotechnology firms. The lack of revenue impacts profitability and cash flow negatively, while a strong cash position provides some buffer. Continued reliance on external financing highlights the need for successful product development and commercialization to improve financial health.

Income Statement

Hightide Therapeutics Inc is currently not generating any revenue, which is a significant challenge as it affects profitability metrics. The company is experiencing substantial losses, reflected in negative EBIT and Net Income. Without revenue, profitability margins cannot be calculated, underscoring the company's current financial instability.

Balance Sheet

The balance sheet shows a relatively healthy cash position with cash and short-term investments significantly higher than total debt, resulting in negative net debt, which is a positive indicator of liquidity. However, the company has had negative stockholders' equity in previous years, indicating potential financial distress. The improvement in equity position in the latest year is a positive sign but needs to be sustained.

Cash Flow

Cash flow analysis reveals consistent negative operating cash flow, highlighting ongoing cash burn without revenue generation. The absence of free cash flow growth and reliance on financing activities for cash inflows presents a risk. While the company has managed to maintain cash reserves, the cash flow situation remains precarious without incoming revenue.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	-2.02M	-1.30M	-1.56M
EBITDA	-196.37K	-444.22K	-1.04B	-229.56M	-131.80M
Net Income	-291.16K	-381.79K	-1.04B	-190.24M	-221.15M
Balance Sheet
Total Assets	528.48M	559.93M	795.04M	855.82M	777.23M
Cash, Cash Equivalents and Short-Term Investments	467.01M	490.52M	735.70M	828.33M	763.91M
Total Debt	99.47M	77.91M	16.43M	1.27B	1.01B
Total Liabilities	160.66M	135.76M	92.26M	1.33B	1.05B
Stockholders Equity	315.51M	424.17M	702.77M	-470.53M	-271.77M
Cash Flow
Free Cash Flow	-112.44M	-299.46M	-368.56M	-172.90M	-90.12M
Operating Cash Flow	-107.85M	-294.81M	-367.67M	-172.71M	-88.40M
Investing Cash Flow	65.21M	-89.72M	321.64M	-415.66M	1.59M
Financing Cash Flow	60.92M	54.79M	399.46M	46.03M	493.98M

Hightide Therapeutics Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2511, the sentiment is Negative. The current price of 3.05 is above the 20-day moving average (MA) of 2.79, above the 50-day MA of 2.99, and above the 200-day MA of 2.97, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 40.13 is Neutral, neither overbought nor oversold. The STOCH value of 13.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2511.

Hightide Therapeutics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	61 Neutral	HK$1.93B	238.10	0.99%	―	9.41%	-32.69%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
6998	50 Neutral	HK$5.20B	58.33	2.04%	―	1447.56%	―
2511	46 Neutral	HK$1.38B	-3.89	-67.27%	―	―	47.42%
2181	45 Neutral	HK$2.27B	-76.39	-25.72%	―	178.36%	86.74%
2137	43 Neutral	HK$1.10B	-2.73	-14.48%	―	―	-41.48%
2126	41 Neutral	HK$1.12B	-1.64	-51.56%	―	2.45%	2.58%

Hightide Therapeutics Inc Corporate Events

HighTide Therapeutics Sets Up Nomination Committee to Bolster Governance

HighTide Therapeutics, Inc. has formally established a Nomination Committee of its board of directors, effective from the date its shares were listed on the Hong Kong Stock Exchange, to oversee the nomination and governance process for directors and senior management. The creation of this committee, and the related governance framework defining key roles and responsibilities, signals a further alignment with Hong Kong listing requirements and best practices in corporate governance, which may enhance transparency, board oversight and confidence among investors and other stakeholders.

HighTide Therapeutics’ HTD1801 Outperforms in Phase III Trial

HighTide Therapeutics announced positive results from its Phase III HARMONY trial, where its drug HTD1801 showed superior improvements in cardiometabolic markers for patients with type 2 diabetes mellitus compared to dapagliflozin. The trial’s success underscores HTD1801’s potential as a foundational therapy in CKM disease management, and the company plans to submit a New Drug Application later this year.

HighTide Therapeutics Showcases Renal Benefits of HTD1801 at ASN Meeting

HighTide Therapeutics presented evidence at the ASN Annual Meeting showing that their drug HTD1801 benefits patients with mild renal impairment by improving eGFR trajectory and normalizing renal function. This development highlights HTD1801’s potential as a foundational therapy in CKM disease management, reinforcing the company’s strategic focus on delivering comprehensive treatments for chronic metabolic diseases.

HighTide Therapeutics Reports Positive Phase III Results for HTD1801 in Diabetes Treatment

HighTide Therapeutics, Inc. announced positive results from two Phase III trials of HTD1801, demonstrating durable efficacy and safety over 52 weeks in treating type 2 diabetes mellitus (T2DM). The trials, SYMPHONY-1 and SYMPHONY-2, showed significant reductions in glycated hemoglobin (HbA1c) and maintained improvements in cardiometabolic and renal endpoints. The company plans to submit a new drug application for HTD1801 in China, highlighting its potential as a foundational therapy in CKM disease management.